Obstacles to the Adoption of Biosimilars for Chronic Diseases

JAMA. 2017 Jun 6;317(21):2163-2164. doi: 10.1001/jama.2017.5202.

Authors

Aaron Hakim¹, Joseph S Ross²

Affiliations

¹ Yale University School of Medicine, New Haven, Connecticut.
² Section of General Internal Medicine and Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut3Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.

PMID: 28459924
DOI: 10.1001/jama.2017.5202

No abstract available

MeSH terms

Biosimilar Pharmaceuticals / economics
Biosimilar Pharmaceuticals / therapeutic use*
Chronic Disease / drug therapy*
Diffusion of Innovation
Drug Approval
Drug Costs*
Drug Industry
Humans
Insurance, Pharmaceutical Services
Legislation, Drug
Pharmacies
State Government
United States

Substances

Biosimilar Pharmaceuticals